GUD — Knight Therapeutics Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeSmall CapSuper Stock

Annual cashflow statement for Knight Therapeutics, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	C2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	18	31.8	15.7	-29.9	-16.8
Depreciation
Deferred Taxes
Non-Cash Items	-8.37	-50.5	-9.33	37.9	38.4
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	-10.2	-23.6	-2.01	-8.49	-26.9
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accrued Expenses
Change in Payable / Accrued Expenses
Change in Taxes Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	4.6	-12.2	44.6	45	35.9
Capital Expenditures	-2.95	-20.7	-224	-25.8	-9.96
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-8.91	122	119	-37.3	39.3
Acquisition of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-11.9	101	-105	-63.1	29.3
Financing Cash Flow Items	0.655	0.231	0.297	-4.18	-9.5
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-62.8	-29.2	-78.3	-2.76	-81
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	-70.5	55.3	-144	-14.3	-12.9